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Abstract
Although treatment of BRAF V600E–mutant non–small cell
lung cancer (NSCLCV600E) with GSK2118436 has shown an
encouraging efﬁcacy, most patients develop resistance. To
investigate the mechanisms of acquired resistance to
GSK2118436 in NSCLCV600E, we established GSK2118436-
resistant (GSR) cells by exposing MV522 NSCLCV600E to
increasing GSK2118436 concentrations. GSR cells displayed
activated EGFR–RAS–CRAF signaling with upregulated EGFR
ligands and sustained activation of ERK1/2, but not MEK1/2, in
the presence of GSK2118436. Treatment of GSR cells with
GSK2118436 enhanced EGFR-mediated RAS activity, leading
to the formation of BRAF–CRAF dimers and transactivation of
CRAF. Interestingly, sustained activation of ERK1/2 was partly
dependent on receptor-interacting protein kinase-2 (RIP2)
activity, but not on MEK1/2 activity. Combined BRAF and
EGFR inhibition blocked reactivation of ERK signaling and
improved efﬁcacy in vitro and in vivo. Our ﬁndings support the
evaluation of combined BRAF and EGFR inhibition in
NSCLCV600E with acquired resistance to BRAF inhibitors.
Mol Cancer Ther; 15(7); 1627–36. 2016 AACR.
Introduction
Non–small cell lung cancer (NSCLC) is the leading cause of
cancer-related deathsworldwide (1).Over the past decade,molec-
ularly targeted therapies, which block important oncogenic path-
ways, have made remarkable progress. Treatment with EGFR and
anaplastic lymphoma kinase tyrosine kinase inhibitors (TKI) in
molecularly selected population has led to unprecedented
improvements in objective response rate (ORR) and progres-
sion-free survival over cytotoxic chemotherapy (2–4).
Aberrant activation of the MAPK pathway, which plays a major
role in cell proliferation, survival, and differentiation, contributes
to various types of cancers. BRAF is a serine/threonine kinase of
the RAF family kinases, which also include ARAF and CRAF. BRAF
serves as a central intermediate in transmitting extracellular sig-
nals to the dual-speciﬁcity protein kinase MEK1/2, which in turn
activates ERK1/2 (5). BRAF is commonly activated by a somatic
mutation at codon 600 (V600E) in various tumor types, including
40% to 50% of cutaneous melanomas and 10% of colorectal
cancers (6). The RAF–MEK–ERK pathway is a key downstream
effector of the small GTPase RAS, the most frequently mutated
oncogene in human cancers (7). Furthermore, RAS is a key
downstream effector of the growth factor receptor, which is
mutationally activated and/or overexpressed in multiple tumor
types (5, 7).
Oncogenic BRAF V600Emutations are present in approximate-
ly 1.3%ofNSCLCs and are thought to result in constitutive kinase
activation and downstreamphosphorylation (8). Theﬁnding that
lung-speciﬁc expression of the BRAF V600E mutation in mouse
models leads to development of invasive adenocarcinoma further
supports the potential role of BRAF V600E as an oncogenic
mutation in NSCLC (9). Very recently, a phase II trial of a BRAF
inhibitor, GSK2118436 (dabrafenib), showed signiﬁcant antitu-
mor activity with a reported ORR of 32% in advanced BRAF
V600E–mutant NSCLC (NSCLCV600E; NCT01336634). However,
clinical efﬁcacy of the BRAF inhibitor is limited by the emergence
of drug resistance, as responses are transient and tumors eventu-
ally recur. These clinical observations make it crucial to under-
stand the mechanisms underlying resistance to BRAF inhibitors
and to identify therapeutic strategies for treatment of NSCLCV600E
with acquired resistance to BRAF inhibitors.
In this study, our objective was to understand the acquired
resistance mechanism to BRAF inhibitors in NSCLCV600E.
Materials and Methods
Cell lines
MV522 were obtained from Dr. Alex A. Adjei (Roswell Park
Cancer Institute, Buffalo, NY) in March 2014. HCC364 human
lung cancer cell line harboring the BRAFV600E mutation was
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obtained from Dr. Adi F. Gazdar (Hamon Center for Therapeu-
tic Oncology Research and Department of Pathology, Univer-
sity of Texas Southwestern Medical Center, Dallas, TX) and
A375 human melanoma cell lines were obtained from Korea
Cell Line Bank in March 2016. Cell lines were maintained at
37C in a humidiﬁed atmosphere at 5% CO2 and grown in
RPMI1640 media supplemented with 10% FBS, 50 units mL1
penicillin and 50 mg mL1 streptomycin (HyClone, GE Health-
care). Authetication of the cell lines was done using short
tandem repeat analyses.
Chemicals, reagents, and antibodies
GSK2118436 and geﬁtinib were purchased from Selleckchem.
Cetuximab was supplied by ImClone Systems. Anti-phospho-
EGFR (Y1068; #3777), anti-EGFR (#2232), anti-phospho-BRAF
(S445, #2696), anti-BRAF (#9433), anti-phospho-CRAF (S338,
#9427), anti-CRAF (#9422), anti-phospho-ERK (T202/Y204,
#9101), anti-ERK (#9106), anti-phospho-AKT (S473, #9271),
anti-AKT (#9272), anti-phospho-MEK (S217/221, #9154), anti-
MEK (#9126), anti-phospho-RIP2 (S176, #14397), RIP2
(#4142), anti-phospho-MET (Y1234/1235, #3129), and anti-
MET (#8198) were purchased from Cell Signaling Technology.
Anti-b-actin (#A3854) was purchased from Sigma-Aldrich. All
donkey anti-rabbit IgG-HRP (#sc-2077) and donkey anti-mouse
IgG-HRP (#sc-2096) were purchased from Santa Cruz
Biotechnology.
Cell viability
MV522 cells were cultured in increasing concentrations of
GSK2118436 from 0.01 to 3 mmol/L to generate polyclonal
resistant clones (GSR pool). Single-cell clones (GSR#1 and
GSR#2) were isolated by limiting dilution from GSR pool. For
MTT assay, cells were seeded in 96-well plates (2  103 cells/
well) for 24 hours. Inhibitors were added and incubated for 72
hours. After MTT solution was added, plates were incubated for
4 hours, and the results were measured at 540 nm. For colony
formation assay, cells were plated into 6-well plates (5  104
cells/well) and treated with inhibitors. After 14 days, cells were
ﬁxed in 3% paraformaldehyde and stained with 0.005% crystal
violet.
gDNA extraction and Sanger sequencing
Genomic DNA was extracted using the DNeasy Blood and
Tissue Kit (Qiagen; #69504) according to the instructions of the
manufacturer. BRAF and RAS genes were ampliﬁed from genomic
DNA by PCR. PCR products were puriﬁed using QIAquick PCR
Puriﬁcation Kit (Qiagen; #28104), followed by Sanger sequenc-
ing using previously reported primer (listed in Supplementary
Table S1) set (1).
siRNA knockdown
siRNA was synthesized by IDT (the sequence of siRNA listed in
Supplementary Table S2) and was transfected into the cells using
Lipofectamine RNAiMAX (Invitrogen; #13778) according to the
manufacturer's instructions.
RAS activity assay
Ras activity was measured using the Ras Activation ELISA Assay
Kit (Cell Biolabs; #STA441). Brieﬂy, cell lysates were incubated
with Raf1-Ras–binding domain (RBD) agarose. Raf1-RBD was
used to capture the activeGTP-bound Ras protein, whichwas then
detected by the addition of an anti-Ras-antibody. An HRP-con-
jugated secondary antibody was then added. A luminometer was
used to measure the signals after addition of a chemiluminescent
reagent (PerkinElmer).
Receptor tyrosine kinase arrays
The Human Phospho-RTK Array Kit (R&D Systems;
#ARY001B) was used to detect kinase activation within a panel
of receptor tyrosine kinases (RTK) according to themanufacturer's
instructions. Brieﬂy,MV522 cells andGSR (pool) cellswere plated
in 10-cmdishes and collected after 24hours. Lysatewas applied to
a membrane-anchored RTK array and incubated at 4C for 24
hours. Membranes were exposed to chemiluminescent reagents
and detected by X-ray ﬁlm (AGFA).
Immunoblotting
Cells were washed in PBS and lysed in a lysis buffer (Cell
Signaling Technology; #9803). Protein concentrationswere deter-
mined by the Bradford Assay Kit (Bio-Rad). Equal amounts of cell
extractswere separatedby SDS-PAGE, transferred tonitrocellulose
membranes (Millipore), and immunoblotted with speciﬁc pri-
mary and secondary antibodies. Membranes were exposed to
chemiluminescent reagents and detected by X-ray ﬁlm (AGFA).
IHC
Sacriﬁced tumors were ﬁxed in 10% neutral-buffered forma-
lin and parafﬁn embedded. Endogenous peroxidase activity
was quenched with 10% hydrogen peroxide in methanol. The
sections were blocked with normal serum for 1 hour and then
incubated overnight with anti-p-EGFR (Y1068), anti-phospho-
ERK, Ki67 (Santa Cruz Biotechnology; #sc-23900), and anti-
pRIP2 (S176; 1:200). The peroxidase-conjugated secondary
antibodies (Dako) were incubated for 1 hour at room temper-
ature. Staining intensity was scored as 0 (absent), 1þ (low-
moderate), and 2þ (high).
RT-PCR and real-time PCR assay
RNAwas extracted using theRNeasymini Kit (Qiagen; #74104)
according to the instructions of the manufacturer. Extracted RNA
was used for the synthesis of cDNA by SuperScript III First-Strand
Synthesis SuperMix (Invitrogen), following the kit manual, and
RT-PCRwas performed on Applied Biosystems StepOnePlus with
SYBR-Green PCRMasterMix (Life Technologies). GAPDH expres-
sion was used as an internal reference to normalize input cDNA.
Xenograft studies
Animal care was performed in accordance with institutional
guidelines. Treatment was by oral gavage daily with vehicle, 300
mg/kg GSK2118436, geﬁtinib 50 mg/kg, or the last two together.
Tumor size was determined by caliper measurements of tumor
length, width, and depth, and volumewas calculated as volume¼
0.5236  length  width  depth (mm).
Statistical analysis
Quantitative results were analyzed by one-wayANOVAor t test.
Statistical signiﬁcance was established for P < 0.05.
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Results
Establishment and characterization of BRAF V600E–mutant
NSCLC cells with acquired resistance to GSK2118436
To explore the mechanisms of acquired resistance to
GSK2118436 in lung cancer, BRAF V600E–mutant MV522 lung
adenocarcinoma cells were cultured in increasing concentra-
tions (up to 3 mmol/L) of the inhibitor. After approximately 3
months, we established cells (GSR-pool, GSR#1, GSR#2) with
strong resistance to GSK2118436 (IC50 > 10 mmol/L;
Fig. 1A; Table 1). Using an MTT assay, we observed the
dose-dependent antiproliferative effect of GSK2118436 in
MV522 cells, but growth inhibition was not detected in GSR
(pool), GSR#1, and GSR#2 (Fig. 1B). These results correlated
with results obtained by a long-term (2 weeks) colony forma-
tion assay (Fig. 1C).
Like in BRAF V600E–mutant melanoma (melanomaV600E),
bidirectional Sanger sequencing of all 18 BRAF exons in all three
GSR clones revealed no gatekeeper mutations in BRAF and reten-
tion of the original BRAF V600E mutation (Fig. 1D; Table 1;
ref. 10). Furthermore, therewasno secondaryNRAS, KRAS,HRAS,
or MEK1 mutation, which could explain resistance to
GSK2118436 (Table 1).
Figure 1.
Establishment and characterization of GSK2118436-resistant clones. A, relative survival of MV522 cells and GSK2118436-resistant clones (GSR-pool, GSR#1,
GSR#2) after treatment of GSK21128436 for 72 hours. B, in MTT assays, all cells were treated with the indicated concentrations of GSK2118436 for 72 hours.
C, in colony formation assays, cells were grown in the absence or presence of the indicated concentrations of GSK2118436 for 14 days. All cells were ﬁxed, stained
with crystal violet (0.005%), and photographed. Photographs of ﬁxed cells are positioned with graphs to represent quantiﬁcation. All data are displayed as
meanSEM (n¼ 3; ,P<0.05;  ,P<0.01;  ,P<0.001). D, Sanger sequencing ofDNA fromeach cells showing retentionofBRAF (V600E)mutation. E,Westernblot
analysis of all cell lysates with indicated antibodies.
Table 1. Characterization of MV522 cells and resistant clones to GSK2118436
Cells NRAS KRAS HRAS BRAF BRAF exon 1–14, 16–18 MEK1 IC50 (mmol/L)
MV522 N/D N/D N/D V600E N/D N/D 0.00176
GSR (Pool) N/D N/D N/D V600E N/D N/D >10
GSR#1 N/D N/D N/D V600E N/D N/D >10
GSR#2 N/D N/D N/D V600E N/D N/D >10
NOTE: Mutation status of BRAF, MEK, and RAS genes are summarized for MV522 cells and GSR cells.
Abbreviation: N/D, not detected.
Acquired Resistance to GSK2118436 in V600E-Mutant NSCLC
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Compared with MV522 cells, GSR cells exhibited higher basal
levels of p-ERK1/2, suggesting that the mechanism of acquired
resistance may be ERK-dependent (Fig. 1E). ERK1/2 activation in
GSR cells was associated with CRAF phosphorylation at S338,
indicative of activation of CRAF kinase (Fig. 1E). Interestingly, the
robust increase of p-ERK1/2 levels in GSR cells were seen without
clear evidence of MEK1/2 activation. Together, these data suggest
that high basal levels of p-CRAF and p-ERK1/2, but not acquired
mutations in MAPK pathway genes, might account for the resis-
tance to GSK2118436 in GSR cells.
GSK2118436-resistant clones display sustained
phosphorylation of ERK that is independent of MEK1/2
We further examinedwhether resistant clones are dependent on
sustained activation of CRAF and ERK1/2 for survival (Fig. 2A and
B). Consistent with the cell viability data, Western blot analysis
showed that GSK2118436 treatment signiﬁcantly suppressed
both p-MEK1/2 and p-ERK1/2 in MV522 cells, whereas it sup-
pressed p-MEK1/2, but not p-ERK1/2, in GSR clones (Fig. 2A). In
melanomaV600E, ERK1/2 inactivation following BRAF inhibition
was reported to relieve the negative feedback suppression of
upstream RTK/RAS signaling, leading to the dimerization and
activation of RAF isoforms (11). Consistent with previous ﬁnd-
ings in melanomaV600E, acute ERK1/2 inactivation following
GSK2118436 treatment induced CRAF activation in MV522 cells
(Fig. 2A). However, CRAF and ERK1/2 are constitutively activated
regardless of GSK2118436 treatment in GSR clones. The consti-
tutive activation of CRAF inGSR clones suggests that theremay be
constitutive upstream activation, such as an NRAS mutation
(which was excluded by Sanger sequencing; Supplementary Table
S1) or RTK activation. Strikingly, unlikemelanoma and colorectal
cancer (10, 12–15), GSK2118436 treatment resulted in dose-
dependent suppression of MEK1/2 activity but resulted in no
signiﬁcant alterations in p-ERK1/2 levels in GSR clones (Fig. 2A).
The pharmacologic uncoupling between MEK1/2 and ERK1/2
activity suggests that MEK1/2 may not directly regulate ERK1/2
activity in GSR clones.
The differential dependence of MV522 and GSR clones on
MEK1/2 signaling for cell survival was clearly shown in cell
viability assays (Fig. 2B). AZD6244, a MEK1/2 inhibitor, potently
inhibited cell growthofMV522 cells in a dose-dependentmanner.
In contrast, GSR clones exhibited resistance at high doses
of AZD6244. Combined inhibition of BRAF and MEK is associ-
ated with complete inhibition of the MAPK pathway in
melanomaV600E, leading to enhanced cytotoxicity and clinical
activity (16). In GSR cells, however, cotreatment of GSK2118436
and AZD6244 did not show synergistic growth inhibition, which
further supports the existence of signaling pathway for ERK1/2
activation bypassing MEK1/2 inhibition (Fig. 2C).
Together, these data suggest that activated CRAFmay transduce
prosurvival signals to ERK1/2 and that sustained activation of
ERK1/2 is independent of MEK1/2 activity.
Figure 2.
ERK1/2 activation is independent of MEK1/2 activity in GSR clones. A, cells were treated with GSK2118436 at the indicated concentration, and lysates were
probed with the indicated antibodies. B, in MTT assays, cells were treated with the indicated concentration of AZD6244 for 72 hours ( , P < 0.05;  , P < 0.01).
C, MV522 cells and GSR cells were treated in control (CTL) or with 0.1 mmol/L GSK2118436 or 1 mmol/L AZD6244 (AZD) or in their combination for 72 hours.
All data are displayed as mean  SEM (n ¼ 3).
Kim et al.
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Autocrine HB-EGF–EGFR signaling confers acquired resistance
to GSK2118436 via activation of RAS-CRAF
In melanomaV600E, RTK activation increases the level of RAS-
GTP, promotes dimerization of RAF isoforms, and reactivates ERK
signaling, leading to resistance to BRAF inhibitors (12). Given the
constitutive CRAF activation in GSR clones, we hypothesized that
phosphorylation of CRAFmay bemediated by activated RTKs. To
determine whether activation of RTK signaling might account for
the observed CRAF activation, we performed phospho-RTK arrays
in MV522 and GSR cells. Interestingly, GSR cells displayed higher
level of p-MET and p-EGFR thanMV522 cells (Fig. 3A), whichwas
conﬁrmed by Western blotting (Fig. 3B and Supplementary Fig.
S1A). Despite overexpression of p-MET in GSR cells, a selective
MET inhibitor, SU11274, did not show signiﬁcant antitumor
activity as a single agent or in combination with GSK2118436
(Supplementary Fig. S1B). Therefore, EGFR activation seemed to
be a major mechanism of acquired resistance to GSK2118436 in
GSR cells. Compared with MV522 cells, GSR clones showed
greater phosphorylation of EGFR (Y1068) but unchanged p-AKT
(S473; Fig. 3B).Notably,GSR clones showed greater levels ofGTP-
bound RAS, suggesting that activated EGFR stimulates RAS-GTP
formation and promotes downstream signaling through CRAF
activation (Fig. 3C).
On the basis of constitutive EGFR activation, we reasoned that
upregulation of EGFR ligands could contribute to resistance to
GSK2118436 in GSR cells. Compared with MV522 cells, the
mRNA expression levels of several EGFR ligands, including TGFa,
epiregulin, amphiregulin, and heparin-binding EGF (HB-EGF),
were signiﬁcantly increased in GSR clones (Supplementary
Fig. S2A). Among the ligands, HB-EGF was the most signiﬁcantly
upregulated in GSR cells (7-fold). In addition, HB-EGF
treatment rescued GSK2118436-induced suppression of p-
ERK1/2, but not at all p-MEK1/2 in MV522 cells (Supplementary
Fig. S2B). Suppression of p-ERK1/2 was also rescued by HB-EGF
stimulation in HCC364 cells (Supplementary Fig. S2B). We
observed no effect of other ligands on ERK1/2 activation. Con-
sistentwith these effects on signaling, treatmentwithHB-EGF, but
not the others, dramatically enhanced MV522 cell viability in the
presence of GSK2118436 (Fig. 3D), indicating that HB-EGF–
mediated hyperactivation of EGFR might promote resistance to
BRAF inhibition. Indeed, only HB-EGF treatment exerted strong
protective effects against GSK2118436, as assessed by a colony
formation assay (Fig. 3E). GSK2118436-induced suppression of
p-ERK1/2 and enhanced cell viability mediated by HB-EGF treat-
mentwere not observed in BRAFV600E–mutant A375melanoma
cell line (Supplementary Fig. S3A and S3B).
Together, our results suggest that autocrine HB-EGF–EGFR
signaling promotes acquired resistance to GSK2118436 via
EGFR-dependent RAS activation.
Inhibition of EGFR restores sensitivity to GSK2118436 by
suppressing RAS-mediated CRAF transactivation in GSR clones
Next, we determined whether combined inhibition of EGFR
could restore sensitivity to GSK2118436 in GSR cells. In cell
viability assays, the GSR clones were insensitive to geﬁtinib (an
EGFR TKI) or cetuximab (an anti-EGFR mAb) monotherapy (Fig.
4A). Notably, combination of either geﬁtinib or cetuximab with
GSK2118436 showed signiﬁcant synergistic antitumor effects in
MTT assays and colony formation assays (Fig. 4A and B). We used
a GTP-RAS activity assay and Western blot analysis to measure
the activation status of EGFR–RAS–RAF–MAPK signaling
Figure 3.
Activation of EGFR–RAS signaling confers resistance toGSK2118436 inGSRcells. A, phospho-RTKarrays showedactivation of EGFRand c-MET inGSR cells. B, cellular
lysates were probed with the indicated antibodies in Western blots. C, GTP-bound RASs were measured by a RAS-GTP pulldown assay in all cells. D, in MTT
assays, MV522 cellswere treated in control or with 1 mmol/L GSK2118436 after treatment with each ligand. E, colony formation assay of MV522 cells after cotreatment
of each ligand and GSK2118436 at the indicated concentration for 14 days. All cells were ﬁxed, stained with crystal violet (0.005%), and photographed. All
data are normalized to MV522 or control and are displayed as mean  SEM (n ¼ 3;  , P < 0.01; ns, not signiﬁcant).
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components in MV522 cells and GSR clones during treatment
with GSK2118436 alone or in combination with geﬁtinib or
cetuximab (Fig. 4C and D). The baseline RAS activity in the
absence of GSK2118436 was signiﬁcantly higher in GSR clones
than MV522 cells (P < 0.05). Furthermore, RAS activities in both
GSR and MV522 cells treated with GSK2118436 were enhanced
over the baseline control, which was signiﬁcantly more pro-
nounced in GSR cells (75% increase in GSR vs. 45% increase in
MV522, P < 0.01). Importantly, rebound increase in the RAS
activities upon GSK2118436 in both GSR and MV522 cells were
abrogated by combining GSK2118436 with geﬁtinib or cetuxi-
mab, which was also signiﬁcantly more pronounced in GSR cells
(65% reduction in GSR vs. 35% reduction in MV522, P < 0.01),
suggesting a dominant role of EGFR on RAS activation in GSR
cells.
Furthermore, when compared with GSK2118436 or EGFR
inhibitor monotherapy, the combination of GSK2118436 with
either geﬁtinib or cetuximab markedly reduced the levels of p-
EGFR, p-CRAF, and p-ERK1/2 in GSR clones. Particularly, cotreat-
ment of GSK2118436 and geﬁtinib inhibited p-ERK1/2 almost
completely in allGSR clones, similar to the effects ofGSK2118436
treatment inMV522 cells. GSK2118436 or EGFR inhibitormono-
therapy could not efﬁciently abolish activation of EGFR–CRAF–
ERK signaling in GSR clones (Fig. 4D). EGFR inhibitor treatment,
either alone or in combination with GSK2118436, did not
decrease the level of p-AKT in GSR clones, indicating that EGFR
activation might not contribute to AKT phosphorylation in these
resistant cells (Fig. 4D). p-EGFR and RAS-GTP were increased in
MV522 cells, likely due to feedback activation of EGFR signaling
upon MAPK pathway inhibition (Fig. 4C and D).
Next, we evaluated whether the increased amount of p-CRAF
directly activated ERK1/2 in GSR cells. Knockdown of CRAF by
siRNA did not affect ERK activity in GSR cells, suggesting that
activated CRAF may not be directly responsible for activation of
ERK1/2 (Fig. 4E).
RAF inhibitors were reported to transactivate RAF dimers and
enhance ERK1/2 signaling inBRAFwild-typemelanoma, and RAF
inhibitor–induced RAF dimerization is RAS dependent (17).
Given the high level of GTP-bound RAS and activated CRAF in
GSR clones, we sought to determine whether GSK2118436
Figure 4.
Inhibition of EGFR restores sensitivity to GSK2118436 by suppressing RAS-mediated CRAF transactivation in GSR clones. A, cells were treated in control or with 1
mmol/L geﬁtinib (GEF), 1 mmol/L cetuximab (CTX), or 0.1 mmol/L GSK2118436 (GSK), alone or in combination for 72 hours, and viable cells were determined
by MTT assay. B, in colony formation assay, cells were ﬁxed, stained, and photographed after treatment with the indicated inhibitors at the same concentration as
in Fig. 5A for 14 days. Graphs, quantiﬁcation of colony. All data are normalized to GSR cells with GSK2118436 treatment and are displayed as mean  SEM (n ¼ 3;
 , P < 0.01). C, cells were treated with the indicated inhibitor alone or in combination for 24 hours, and levels of active GTP-bound RAS were determined by
a RAS-GTP ELISA assay. Error bars, mean  SEM (n ¼ 3).  , P < 0.05, GSR cells versus MV522 cells in control;  , P < 0.01; , P < 0.001, control versus geﬁtinib or
cetuximab in MV522 cells and GSR cells; #, P < 0.05; ##, P < 0.01, control versus GSK2118436 in MV522 cells and GSR cells; $, P < 0.05; $$, P < 0.05, GSK2118436
versus combination of GSK2118436 with geﬁtinib or cetuximab in MV522 cells and GSR cells, respectively. D, lysates were evaluated by Western blots
with the indicated antibodies, and endogenous BRAF was immunoprecipitated (IP), washed, and immunoblotted (IB) for p-CRAF. E, cells were transfected
for 72 hours with scrambled siRNA or CRAF siRNA, respectively. Lysates were probed with the indicated antibodies.
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promoted BRAF-CRAF heterodimer via an immunoprecipitation
assay. Indeed, as in BRAF wild-type melanoma, treatment with
GSK2118436, but not geﬁtinib or cetuximab, induced interaction
between BRAF and CRAF in GSR clones (Fig. 4D). Moreover,
interaction between BRAF and CRAF disappeared upon combi-
nation treatment of GSK2118436 with geﬁtinib or cetuximab in
GSR clones.
Together, these data indicate that GSK2118436-induced for-
mation of BRAF-CRAF heterodimers and CRAF transactivation,
which is dependent on EGFR-mediated RAS activation, is respon-
sible for sustained ERK1/2 activation in GSR cells.
Receptor-interacting protein-2 kinase is partly responsible for
sustained ERK1/2 activation in GSR clones
Receptor-interacting protein (RIP) kinases, which consist of
seven members of serine/threonine kinases (RIP 1–7), have
emerged as essential sensors of cellular stress (18). In response
to various extracellular and intracellular stresses, RIP kinases play
essential roles in prosurvival, inﬂammatory, and immune
responses and in proapoptotic processes. Particularly, RIP2 kinase
mediates the activation of MAPKs, such as p38, JNK, and ERK1/2
(19).
In GSR clones, ERK1/2 activation was independent of MEK1/2,
which was supported by GSK2118436-mediated suppression of
MEK1/2, but not ERK1/2. Thus, we evaluated whether inhibition
of RIP2 by siRIP2 regulates ERK1/2 activation. Knockdown of
RIP2 suppressed p-ERK1/2 in GSR cells, but not in MV522 cells
(Fig. 5A).
Given that the combination of GSK2118436 and EGFR inhi-
bitors suppressed p-ERK1/2 by inhibiting EGFR/RAS/CRAF sig-
naling (Fig. 4D), we evaluated whether the combination treat-
ment also regulates p-RIP2. Compared with GSK2118436 or
EGFR inhibitor monotherapy, the combination of GSK2118436
with either geﬁtinib or cetuximab reduced the level of p-RIP2,
accompanied by inactivation of ERK1/2, only in GSR cells
(Fig. 5B). Next, we examined whether RIP2 inhibition can over-
come acquired resistance toGSK2118436 inGSR cells. Consistent
with the effects of RIP2 on ERK1/2 activation, the antiproliferative
effect of GSK2118436 in GSR cells was increased by cotreatment
of siRIP2 in colony formation assays (Fig. 5C). Overexpression of
RIP2 wild type or RIP2 (S176E; which is phosphorylated form)
induces the resistance to GSK2118436 in MV522 cells compared
with EGFP-C1 vector expressing MV522 cells via retained
phosphorylation of ERK1/2 (Supplementary Fig. S4). Further-
more, RIP2 silencing modestly decreased the mRNA expression
of HB-EGF, but not of the other EGFR ligands in GSR cells
(Supplementary Fig. S5).
Together, these results suggest that RIP2 activation may con-
tribute to the sustained activation of ERK1/2 in GSR cells and
combined inhibition of BRAF and RIP2 could partly overcome
acquired resistance to GSK2118436.
Inhibition of EGFR signaling potentiates the antitumor activity
of GSK2118436 in GSR xenograft models
To further examine whether combined BRAF and EGFR
inhibition can overcome acquired resistance to GSK2118436
in vivo, we tested the effects of GSK2118436, geﬁtinib, and their
combination on the growth of GSR xenograft tumors estab-
lished in nude mice. The combined treatment of GSK2118436
and geﬁtinib showed a strong synergistic inhibition of tumor
growth compared with controls (P < 0.01) or with treatment
with GSK2118436 (P < 0.01) or geﬁtinib alone (P < 0.01; Fig.
6A) in GSR xenografts but not in MV522 xenografts. The
synergistic antitumor effect of combined GSK2118436 and
geﬁtinib treatment was also detected by immunohistochemical
staining for Ki67 (a marker for cell proliferation), p-EGFR, p-
CRAF, p-RIP2, and p-ERK1/2 (Fig. 6B). Consistent with in vitro
observations, staining for Ki67, p-EGFR, p-CRAF, p-RIP2, and
p-ERK1/2 was markedly reduced upon combined administra-
tion of GSK21128436 and geﬁtinib only in GSR xenografts
compared with controls or treatment with GSK2118436 or
geﬁtinib alone. These results support combined inhibition of
Figure 5.
Activation of RIP2 is responsible for
activation of ERK in GSR cells. A, cells
were transfected for 24 hours with
scrambled siRNA and RIP2 siRNA,
respectively, and treated with or without
GSK2118436 for 48 hours. Lysates were
probed with the indicated antibodies. B,
cells were treated with geﬁtinib (GEF) or
cetuximab (CTX) in the absence or
presence of GSK2118436. Lysates were
probed with the indicated antibodies.
CTL, control. C, cells were transfected for
24 hours with scrambled siRNA or RIP2
siRNA, respectively, and treated with or
without GSK2118436 at the indicated
concentration for 14 days before staining
with crystal violet. Data are normalized to
GSR cells with GSK2118436 treatment
and are displayed as mean SEM (n¼ 3;
 , P < 0.01;  , P < 0.001).
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BRAF and EGFR as a promising therapeutic strategy for
NSCLCV600E with acquired resistance to GSK2118436.
Discussion
In our study, we found that sustained ERK1/2 activation via
EGFR-mediated activation of RAS and CRAF confers acquired
resistance to GSK2118436 in NSCLCV600E. Upregulation of the
EGFR ligand, HB-EGF, and autocrine EGFR activation leads to
constitutive activation of the canonical downstream cascade of
EGFR signaling and potentiates resistance to GSK2118436. The
most interesting and novel ﬁnding of our study is that ERK1/2
activation, the critical contributor to BRAF inhibitor resistance, is
independent of MEK1/2 activity but partly dependent on RIP2
kinase activity, which distinguishes BRAF inhibitor–resistant
NSCLCV600E from BRAF inhibitor–resistant melanomaV600E.
To our knowledge, various acquired resistance mechanisms to
BRAF inhibitors have been reported to date (20): alternative
splicing of BRAF (14), BRAF ampliﬁcation (21), CRAF overexpres-
sion (22), and activation of EGFR signaling (15, 23, 24). In the
former mechanism reported in melanomaV600E, p61 splicing
variant (p61BRAF)–driven resistance to BRAF inhibitors reacti-
vated MEK–ERK signaling through enhanced dimerization of the
aberrant BRAF isoform (14). The latter mechanism occurred
through enhanced expression of EGFR ligands that potentiated
autocrine EGFR activation, which promoted both MEK-depen-
dent ERK reactivation and AKT1/2 activation (25), in contrast to
MEK-independent ERK reactivation in our study. Accordingly,
treatment of BRAF inhibitor–resistant cells with erlotinib either
alone or in combination with vemurafenib decreased the level of
p-AKT1/2 in the study, indicating that EGFR activation critically
contributed to AKT1/2 activation (25), whereas treatment of GSR
cells with an EGFR inhibitor alone or in combination with
GSK2118436 herein did not decrease the level of p-AKT1/2
despite signiﬁcant reduction of p-EGFR (Fig. 4D).
Contrary to the previous study (21), the levels of p-EGFR, but
not p-AKT1/2, were different between BRAF inhibitor–sensitive
and -resistant cells in our study (Figs. 3B and 4D), suggesting that
increased p-EGFR levels could be a biomarker of BRAF inhibitor
resistance acquisition in NSCLCV600E. Furthermore, the level of
Figure 6.
Combination of GSK2118436 and geﬁtinib leads to enhanced in vivo efﬁcacy in GSR (pool) cells. A, xenografts derived from MV522 cells and GSR (pool) cells
were treated with vehicle (control), GSK2118436 (GSK, 300 mpk daily), or geﬁtinib (GEF, 50 mpk daily) alone or in combination (GSK þ GEF) for 33 days.
Inhibitor treatments commenced when tumor volume reached 150 mm3, and mean tumor volumes shown (SEM) are normalized to control (n ¼ 7 mice/group;
 , P < 0.01). B, tumors were harvested 6 hours after administration of the ﬁnal dose and evaluated by IHC for p-EGFR, p-ERK1/2, p-RIP2, p-CRAF, and a
marker of cell proliferation (Ki67). Representative examples are shown. C, the mechanism of acquired resistance to GSK2118436 in NSCLCV600E. In MV522 cells,
BRAF controls cell growth and proliferation via MEK–ERK signaling. GSK2118436 effectively inhibits cell growth via the MEK-ERK pathway (left). However,
GSR cells show diminished dependence on BRAF–MEK–ERK signaling. Activation of EGFR causes increasing RAS activity in the presence of GSK2118436 and
promotes CRAF transactivation by dimerization with BRAF. Activation of RIP2 in these resistant cells is caused by both BRAF inhibition and EGFR–RAS–CRAF
activation, and activated RIP2 sustains cell growth by reactivating ERK1/2 in the presence of GSK2118436 (right).
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p-EGFR may contribute to distinguish BRAF inhibitor–resistant
NSCLCV600E with EGFR dependence from that with MAPK reac-
tivation by other mechanisms, such as mutation of the MAPK
pathway genes. Discrimination between at least these two
mechanismswill be important for developing treatment strategies
to overcome resistance to BRAF inhibitors. For example, as in
melanomaV600E, p61BRAF-driven MAPK pathway reactivation
can be subverted by combined BRAF and MEK inhibition (16).
A current clinical trial is testing whether a combination of
GSK2118436 and trametinib (GSK1120212) can delay or prevent
acquired drug resistance in patients with NSCLCV600E
(NCT01336634). However, our in vitro and in vivo data clearly
suggest that a subset of BRAF inhibitor–resistant NSCLCV600E
patients with EGFR-mediated MAPK pathway reactivation might
beneﬁt most from combined inhibition of BRAF and EGFR.
Importantly, nearly complete inhibition of p-ERK1/2, which is
an essential prerequisite for tumor responses to BRAF inhibitor,
and signiﬁcantly reduced GTP-bound RAS and p-CRAF were
observed only after combined treatment with GSK2118436 and
EGFR inhibitors.MEK-independent activation of ERK1/2 and lack
of synergistic antitumor effects with cotreatment of GSK2118436
and AZD6244 (Fig. 2C) does not support further clinical inves-
tigation of combined BRAF and MEK inhibition in this subset of
NSCLCV600E.
As in BRAF wild-type melanoma (17), GSK2118436
enhanced BRAF–CRAF dimerization and transactivated CRAF,
resulting in paradoxical activation of ERK1/2, and drug-medi-
ated transactivation of RAF dimers was dependent on RAS
activity. Indeed, there was a signiﬁcant recovery of p-EGFR
following GSK2118436 treatment in GSR cells (Fig. 4D), likely
due to feedback activation of EGFR caused by BRAF inhibition
(26). Furthermore, in addition to higher baseline RAS activity,
GSR cells exhibited far greater enhancement of RAS activity
after treatment with GSK2118436 than MV522 cells. Given the
lack of RAS mutation and inhibition of RAS activity with EGFR
inhibitor treatment either alone or in combination with
GSK2118436 in GSR cells, we attributed RAS activation to
autocrine activation of EGFR in our resistant model. Impor-
tantly, the maximum enhancement of EGFR and RAS activity in
the presence of GSK2118436 might contribute to efﬁcient
formation of BRAF-CRAF heterodimers, ultimately leading to
sustained ERK activation and drug resistance. In contrast,
enhancement of RAS activity was less pronounced in MV522
cells than in GSR cells, resulting in dissociation of the BRAF–
CRAF complex and, therefore, minimal activation of CRAF.
Most interestingly, we found that sustained activation of
ERK1/2 could be partly dependent on RIP2 activity, but not on
MEK activity, although RIP2 activation is not the major determi-
nant of ERK1/2 activation. To our knowledge, this is the ﬁrst
report on the mechanism of acquired resistance to BRAF inhibi-
tors describing MEK-independent ERK reactivation in any type of
BRAF V600E–mutant cancers. RIP2 is a serine/threonine kinase
that serves as an intracellularmediator of TNF receptor-a response
to assemble a signaling complex leading to apoptosis (27, 28). In
an earlier report, RAS-activated CRAF phosphorylated and acti-
vated RIP2 kinase, which then activated ERK1/2 (29). Herein, we
assumed that RIP2 activation was likely attributable to CRAF
activation driven by EGFR-mediated RAS activity based on abro-
gation of RIP2 activation only after combined treatment with
GSK2118436 and EGFR inhibitor. Finally, the combination of
GSK2118436 and siRIP2 suppress RIP2-mediated ERK reactiva-
tion and cell growth, supporting a role for RIP2 as a contributor to
the acquired resistance to GSK21128436 in GSR cells.
On the basis of this unique mechanism of ERK1/2 reactivation
and its potential druggability, our results suggest that a combi-
nation of BRAF inhibitor and EGFR inhibitor may be a promising
therapeutic strategy for patients with NSCLCV600E with acquired
resistance to BRAF inhibitors.
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Retraction
Retraction: EGFR-Mediated Reactivation of
MAPK Signaling Induces Acquired Resistance
to GSK2118436 in BRAF V600E–Mutant
NSCLC Cell Lines
This study (1)makes extensive use of a purported BRAF-V600E–driven non-small cell
lung cancer (NSCLC) cell line,MV522.However, ATCCdiscontinued offering the cell
line in July, 2012 because "STR yielded similar proﬁles forMV522 (ATCCCRL-2519)
and HT-29 (ATCC HTB-38)" (2). The International Cell Line Authentication Com-
mittee (ICLAC) lists MV522 as a cell line for which no authentic stock is known (3).
The ICLAC states that MV522 cells are not of lung cancer origin but are a cross
contamination of the HT-29 BRAF-V600E–driven colorectal cancer cell line. Because
the claims of the article rest on the cell line being non–small cell lung cancer cells, the
article is being retracted by the editors.
The authors have been informed of this decision.
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